RDHL [NASD]
RedHill Biopharma Ltd.
Index- P/E- EPS (ttm)-2.10 Insider Own12.96% Shs Outstand52.52M Perf Week10.89%
Market Cap42.40M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float34.99M Perf Month-20.55%
Income-97.70M PEG- EPS next Q-0.21 Inst Own13.00% Short Float4.38% Perf Quarter-68.97%
Sales85.80M P/S0.49 EPS this Y-0.50% Inst Trans-1.76% Short Ratio0.77 Perf Half Y-63.36%
Book/sh-0.10 P/B- EPS next Y46.50% ROA- Target Price12.25 Perf Year-87.86%
Cash/sh0.58 P/C1.47 EPS next 5Y- ROE- 52W Range0.62 - 11.18 Perf YTD-67.05%
Dividend- P/FCF- EPS past 5Y1.70% ROI-83.90% 52W High-92.40% Beta2.01
Dividend %- Quick Ratio- Sales past 5Y285.30% Gross Margin52.80% 52W Low37.11% ATR0.12
Employees201 Current Ratio- Sales Q/Q-11.70% Oper. Margin- RSI (14)44.36 Volatility21.53% 14.31%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.20 Prev Close0.88
ShortableYes LT Debt/Eq- EarningsJun 23 BMO Payout- Avg Volume1.99M Price0.85
Recom1.70 SMA20-3.28% SMA50-29.40% SMA200-69.44% Volume2,381,685 Change-3.63%
Aug-31-21Initiated Cantor Fitzgerald Overweight $22
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Jun-24-22 05:31AM  
Jun-23-22 01:01PM  
07:00AM  
Jun-17-22 08:30AM  
May-25-22 09:15AM  
May-10-22 07:37AM  
May-09-22 08:30AM  
May-06-22 11:20AM  
May-04-22 03:17PM  
Apr-14-22 09:55AM  
Apr-11-22 09:00AM  
08:02AM  
Mar-17-22 07:59AM  
Mar-15-22 09:00AM  
Mar-10-22 07:00AM  
Mar-03-22 04:10AM  
Mar-02-22 04:18PM  
Mar-01-22 12:00PM  
09:00AM  
Feb-17-22 09:30AM  
Feb-07-22 01:38PM  
10:15AM  
Jan-18-22 01:38PM  
Jan-13-22 11:51AM  
10:35AM  
Jan-06-22 09:15AM  
Dec-20-21 08:35AM  
08:35AM  
Dec-15-21 09:16AM  
09:15AM  
Dec-14-21 08:35AM  
Dec-09-21 01:05PM  
12:19PM  
07:33AM  
07:15AM  
07:00AM  
Dec-08-21 10:58AM  
Dec-06-21 07:01AM  
07:00AM  
07:00AM  
Dec-03-21 04:41AM  
Dec-02-21 07:01AM  
07:00AM  
Dec-01-21 07:22AM  
07:02AM  
Nov-30-21 09:30AM  
07:02AM  
07:00AM  
07:00AM  
Nov-24-21 07:00AM  
Nov-23-21 11:10AM  
Nov-19-21 02:47PM  
12:07PM  
09:00AM  
Nov-18-21 04:01PM  
Nov-16-21 12:12PM  
Nov-15-21 07:02AM  
07:00AM  
Nov-09-21 07:00AM  
Nov-08-21 07:15AM  
07:00AM  
07:00AM  
Nov-01-21 03:21PM  
Oct-25-21 07:02AM  
07:00AM  
Oct-22-21 05:51AM  
Oct-20-21 07:00AM  
Oct-19-21 08:33AM  
Oct-18-21 07:02AM  
07:00AM  
Oct-12-21 07:02AM  
07:00AM  
Oct-06-21 07:02AM  
07:00AM  
Oct-05-21 07:07AM  
Oct-04-21 05:46PM  
10:33AM  
08:48AM  
08:15AM  
08:00AM  
Sep-23-21 07:00AM  
Sep-15-21 11:40AM  
Sep-14-21 12:02PM  
08:15AM  
Sep-13-21 09:10AM  
07:02AM  
07:00AM  
Sep-08-21 10:29AM  
Sep-07-21 07:56AM  
07:02AM  
06:02AM  
06:00AM  
Sep-02-21 10:35AM  
10:00AM  
Sep-01-21 10:44AM  
Aug-31-21 04:11PM  
Aug-26-21 08:44AM  
07:56AM  
07:50AM  
07:30AM  
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.